At least RVX has a shorter trial timeline than ESPR

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

At least RVX has a shorter trial timeline than ESPR

posted on May 05, 2016 12:10PM

We often compare some of the share price changes and market cap of Resverlogix (RVX) with that of Esperion (ESPR). Of course, RVX-208 and ETC-1002 are different drugs, targets, and mechanism of action. Furthermore, ETC-1002 affects LDL class of lipoproteins and RVX-208 affects HDL class of lipoproteins (amongst several other cardioprotective pathways).

Esperion put out a news release yesterday and I made some comments in the off topic forum if anyone is interested. Their 52-week long-term safety and efficacy trial runs until Dec 2017 and they don't plan to initiate their cardiovascular outcomes trial until Q4 2016.

That's a long time for ESPR investors to wait around for results. Phase 3 BETonMACE, which is a cardiovascular outcomes trial, will be in the homestretch by Dec 2017.